These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 14640929)

  • 1. Evaluation of memantine for the treatment of Alzheimer's disease.
    Ferris SH
    Expert Opin Pharmacother; 2003 Dec; 4(12):2305-13. PubMed ID: 14640929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine hydrochloride: pharmacological and clinical profile.
    Möbius HJ; Stöffler A; Graham SM
    Drugs Today (Barc); 2004 Aug; 40(8):685-95. PubMed ID: 15510240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
    Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine: a review of its use in Alzheimer's disease.
    Robinson DM; Keating GM
    Drugs; 2006; 66(11):1515-34. PubMed ID: 16906789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Memantine].
    Molinuevo JL
    Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
    Ott BR; Blake LM; Kagan E; Resnick M;
    J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease.
    Calhoun A; King C; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2018 Oct; 19(15):1711-1717. PubMed ID: 30244611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine. Merz.
    Kilpatrick GJ; Tilbrook GS
    Curr Opin Investig Drugs; 2002 May; 3(5):798-806. PubMed ID: 12090556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.
    Lyseng-Williamson KA; McKeage K
    Drugs Aging; 2013 Jan; 30(1):51-8. PubMed ID: 23229767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
    Cosman KM; Boyle LL; Porsteinsson AP
    Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.